AstraZeneca’s AZN first-quarter 2025 core earnings of $1.24 per American depositary share (ADS) beat the Zacks Consensus ...

Dr. Reddy's Laboratories has expanded its partnership with Sanofi Healthcare to introduce Beyfortus, a novel drug preventing ...

Sanofi (ENXTPA:SAN) saw a 2.85% increase in its share price last week, coinciding with notable company updates. The pharmaceutical giant announced a dividend increase to €3.92 per share during its ...

Dr Reddy’s and Sanofi partner to launch Beyfortus, a novel drug to prevent respiratory syncytial virus in infants.

This was driven by launches, Dupixent, and favorable Beyfortus phasing. Sales increased 10.8% year over year and 9.7% on constant currency. U.S. sales were 4.66 billion and increased by 15.4%. The ...

Under the agreement, Dr Reddy's will have exclusive rights from SHIPL to promote and distribute Beyfortus within the country ...

Swedish Orphan Biovitrum AB (BIOVF) reports robust revenue growth driven by haematology, while facing challenges in immunology and strategic market expansions.

The strategic portfolio includes Sobi's medicines Altuvoct, Aspaveli/Empaveli, Doptelet, Gamifant, Vonjo and Zynlonta, and royalty on Sanofi's sales of Altuviiio and Beyfortus. The presentation ...

Dr Reddy's Laboratories has partnered with Sanofi Healthcare to introduce Beyfortus, a novel drug for RSV prevention in ...

Dr Reddy’s & Sanofi Healthcare expand partnership to unveil Beyfortus, a novel drug to prevent RSV in India: Our Bureau, Bengaluru Tuesday, April 29, 2025, 12:15 Hrs [IST] Dr Re ...

--U.S. FDA Delays: Sanofi is potentially exposed to any delays in reviews due to recently announced staff firings at the U.S. Food and Drug Administration. Its anti-inflammatory drug Dupixent was ...

The company plans to introduce Beyfortus, which contains the monoclonal antibody nirsevimab, in a prefilled injection used ...